Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07FBM
|
|||
| Former ID |
DNCL002834
|
|||
| Drug Name |
ASP1941
|
|||
| Synonyms |
Ipragliflozin L-proline; 951382-34-6; UNII-M6N3GK48A4; Suglat (TN); Ipragliflozin (L-Proline); M6N3GK48A4; Ipragliflozin L-proline [JAN]; Ipragliflozin L-proline (JAN); Ipragliflozin mixture with proline; DTXSID20241771; EX-A2771; L-Proline compd. with (1S)-1,5-anhydro-1-C-[3-(benzo[b]thien-2-ylmethyl)-4-fluorophenyl]-D-glucitol (1:1); HY-14894A; AKOS027321043; L-Proline, compd. with (1S)-1,5-anhydro-1-C-(3-(benzo(b)thien-2-ylmethyl)-4-fluorophenyl)-D-glucitol (1:1); AK310367; DS-11639; AC-29892; CS-0019749; D10200
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Liver disease [ICD-11: DB90-BD99] | Phase 3 | [1] | |
| Company |
Astellas Pharma US
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C21H21FO5S
|
|||
| Canonical SMILES |
C1=CC=C2C(=C1)C=C(S2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)F
|
|||
| InChI |
1S/C21H21FO5S/c22-15-6-5-12(21-20(26)19(25)18(24)16(10-23)27-21)7-13(15)9-14-8-11-3-1-2-4-17(11)28-14/h1-8,16,18-21,23-26H,9-10H2/t16-,18-,19+,20-,21+/m1/s1
|
|||
| InChIKey |
AHFWIQIYAXSLBA-RQXATKFSSA-N
|
|||
| CAS Number |
CAS 761423-87-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| ChEBI ID |
CHEBI:134724
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Sodium/glucose cotransporter 2 (SGLT2) | Target Info | Modulator | [2], [3] |
| Reactome | Hexose transport | |||
| Na+-dependent glucose transporters | ||||
| Inositol transporters | ||||
| WikiPathways | NRF2 pathway | |||
| Nuclear Receptors Meta-Pathway | ||||
| Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01054092) A Study to Assess the Long-term Safety and Efficacy of ASP1941 in Japanese Diabetic Patients. U.S. National Institutes of Health. | |||
| REF 2 | Ipragliflozin: A novel sodium-glucose cotransporter 2 inhibitor developed in Japan.World J Diabetes.2015 Feb 15;6(1):136-44. | |||
| REF 3 | Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study.Diabetes Obes Metab. 2013 May;15(5):403-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.